USFDA concludes inspection at Lupin’s Nagpur Injectable facility

17 Sep 2025 Evaluate

U.S. Food and Drug Administration (USFDA) has concluded an inspection at Lupin’s Nagpur Injectable facility. USFDA has conducted the said inspection from September 08 to September 16, 2025. The inspection closed with six observations.

The company will address the observations and respond to the U.S. FDA within the stipulated timeframe. The company is committed to be compliant with CGMP quality standards across all its facilities.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. 

Lupin Share Price

2112.95 3.95 (0.19%)
26-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.20
Dr. Reddys Lab 1269.05
Cipla 1505.05
Zydus Lifesciences 911.50
Lupin 2112.95
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×